×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RYTM – rhythm pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RYTM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/5
12:56 pm
rytm
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments [Yahoo! Finance]
Low
Report
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments [Yahoo! Finance]
4/3
09:49 am
rytm
Rhythm Pharmaceuticals Announces Changes to Board of Directors [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Announces Changes to Board of Directors [Yahoo! Finance]
4/3
09:00 am
rytm
Rhythm Pharmaceuticals Announces Changes to Board of Directors
Low
Report
Rhythm Pharmaceuticals Announces Changes to Board of Directors
3/31
04:29 pm
rytm
Is This Weight Loss Drug Stock a Buy After a New Approval? [Yahoo! Finance]
Low
Report
Is This Weight Loss Drug Stock a Buy After a New Approval? [Yahoo! Finance]
3/27
06:17 am
rytm
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment [Yahoo! Finance]
3/26
09:01 am
rytm
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Low
Report
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
3/22
08:29 am
rytm
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity [Yahoo! Finance]
Medium
Report
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity [Yahoo! Finance]
3/22
03:17 am
rytm
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals Wins FDA Approval for IMCIVREE in Acquired Hypothalamic Obesity Launch [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
07:00 am
rytm
rhythm pharmaceuticals, inc.
BEAT
Report
-3.7%
rhythm pharmaceuticals, inc.
11/4/2025
07:00 am
rytm
rhythm pharmaceuticals, inc.
MISS
Report
-7.5%
rhythm pharmaceuticals, inc.
8/5/2025
07:00 am
rytm
rhythm pharmaceuticals, inc.
MISS
Report
-3.7%
rhythm pharmaceuticals, inc.
5/7/2025
07:00 am
rytm
rhythm pharmaceuticals, inc.
MISS
Report
8.4%
rhythm pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
05:36 pm
rytm
Form 4 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Mazabraud Yann
Low
Report
Form 4 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Mazabraud Yann
4/3
05:35 pm
rytm
Form 3 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Popovits Kimberly J
Low
Report
Form 3 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Popovits Kimberly J
4/3
05:35 pm
rytm
Form 4 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Popovits Kimberly J
Low
Report
Form 4 RHYTHM PHARMACEUTICALS, For: Apr 01 Filed by: Popovits Kimberly J
4/3
03:07 pm
rytm
Form 8-K RHYTHM PHARMACEUTICALS, For: Apr 01
Low
Report
Form 8-K RHYTHM PHARMACEUTICALS, For: Apr 01
3/27
11:33 am
rytm
Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: VANGUARD GROUP INC
Medium
Report
Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: VANGUARD GROUP INC
3/26
04:06 pm
rytm
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 26
Medium
Report
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 26
3/20
09:20 am
rytm
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 19
High
Report
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 19
3/16
04:31 pm
rytm
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 16
Low
Report
Form 8-K RHYTHM PHARMACEUTICALS, For: Mar 16
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/7
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
14.9%
3/16 Form 4 RHYTHM PHARMACEUTICALS, For: Mar 13 Filed by: Smith Hunter C 14.5%
10/15 Form 8-K RHYTHM PHARMACEUTICALS, For: Oct 15 13.4%
10/18 Form 3 RHYTHM PHARMACEUTICALS, For: Oct 16 Filed by: RA Capital Healthcare Fund LP 10.2%
4/9 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.0%
11/22 Form 4 RHYTHM PHARMACEUTICALS, For: Nov 20 Filed by: Foley Todd 6.3%
3/2 Q4/2019 12/31/2019 EPS -0.780 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%
12/5 Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes 6.0%
2/25 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference 5.5%
3/30 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities 5.1%
3/16 Form 4 RHYTHM PHARMACEUTICALS, For: Mar 13 Filed by: Smith Hunter C 14.5%
10/15 Form 8-K RHYTHM PHARMACEUTICALS, For: Oct 15 13.4%
10/18 Form 3 RHYTHM PHARMACEUTICALS, For: Oct 16 Filed by: RA Capital Healthcare Fund LP 10.2%
4/9 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 10.0%
11/22 Form 4 RHYTHM PHARMACEUTICALS, For: Nov 20 Filed by: Foley Todd 6.3%
3/2 Q4/2019 12/31/2019 EPS -0.780 ZacksConsensus N/A ActVsEst N/A - N/A 6.2%
12/5 Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes 6.0%
2/25 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference 5.5%
3/30 Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities 5.1%
TOP News Decliners
8/7
Form 8-K RHYTHM PHARMACEUTICALS, For: Aug 07
-9.8%
9/25 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -8.5%
1/10 Form 8-K RHYTHM PHARMACEUTICALS, For: Jan 10 -5.1%
2/26 Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 20 -5.0%
4/30 Form 4 RHYTHM PHARMACEUTICALS, For: Apr 28 Filed by: Foley Todd -4.7%
4/29 Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 17 -4.7%
3/18 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome -4.6%
7/29 Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results -4.2%
6/21 Form 3 RHYTHM PHARMACEUTICALS, For: Jun 19 Filed by: GOOD JENNIFER L -4.1%
1/6 Rhythm Pharmaceuticals Announces Leadership Transition -4.1%
9/25 Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $40.00 price target on the stock. -8.5%
1/10 Form 8-K RHYTHM PHARMACEUTICALS, For: Jan 10 -5.1%
2/26 Form 8-K RHYTHM PHARMACEUTICALS, For: Feb 20 -5.0%
4/30 Form 4 RHYTHM PHARMACEUTICALS, For: Apr 28 Filed by: Foley Todd -4.7%
4/29 Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 17 -4.7%
3/18 Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome -4.6%
7/29 Rhythm Pharmaceuticals Reports Second Quarter 2019 Financial Results -4.2%
6/21 Form 3 RHYTHM PHARMACEUTICALS, For: Jun 19 Filed by: GOOD JENNIFER L -4.1%
1/6 Rhythm Pharmaceuticals Announces Leadership Transition -4.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: